The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.
The key benefit of zerlasiran’s approach is its ability to directly target and silence the gene responsible for Lp(a) ...
Lilly has reported comprehensive outcomes from the Phase III trial of tirzepatide for individuals with heart failure with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback